SYBX News and Press, Synlogic Inc. From 03/29/23

– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform presentation and two poster pr...

2023-03-28 09:13:18 ET The European Medicines Agency (EMA) issued a positive opinion on Synlogic's ( NASDAQ: SYBX ) application seeking orphan designation for SYNB1934 to treat phenylketonuria (PKU). PKU is a rare inherited metabolic disorder which causes an amin...

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company’s application for orphan designa...

CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the company’s Phase 2 Synpheny-1 study for phenylketonuria (PKU) were presented in a podium presentat...

NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held on March 9th are now available for online viewing. REGISTER NOW AT : ...

CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer, and members of the leadership team, will ...

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum to be held March 9 th . Individual investors, institutional investors, advisors, and analysts ...

– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company ...

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced it will participate in the following upcoming investor and industry conferences: BIO CEO & Investor Conference...

The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation (RPDD) to Synlogic's ( NASDAQ: SYBX ) SYNB1934 to potentially treat phenylketonuria (PKU). PKU is a rare inherited disorder which causes an amino acid called phenylalanine to build up in the bod...